Vimarsana
Biggest News Aggregation in the World

Scientific Advice News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scientific Advice. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scientific Advice Today - Breaking & Trending Today

Technical webinar: WHO global sodium benchmarks for different food categories (2nd edition) - Vimarsana News

Technical webinar: WHO global sodium benchmarks for different food categories (2nd edition)

This second edition introduces benchmarks for sodium levels across 70 food subcategories, reflecting WHO's commitment to reducing sodium intake globally. These globally harmonized benchmarks define the maximum levels of sodium that processed foods can contain.

Source: who.int
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development - Vimarsana News

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection As anticipated, an End of Phase 2...

Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea - Vimarsana News

Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea

SAN FRANCISCO - Jaguar Health today announced that Jaguar family company Napo Pharmaceuticals has submitted an Orphan Drug Designation application to the U.S. Food and Drug Administration for...

MCO-010 Gene Therapy for Retinitis Pigmentosa Receives Regulatory Feedback - Vimarsana News

MCO-010 Gene Therapy for Retinitis Pigmentosa Receives Regulatory Feedback

Both the FDA and EU regulators indicated visual acuity may serve as primary endpoint to evaluate MCO-010 in the treatment of low-vision retinitis pigmentosa patients.

Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa - Vimarsana News

Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa

Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for...